Developer docs
API playgroundTry for free, no card

Search company profiles

Cellbri

Full company profile

uuid000265w

Namestring
Cellbri
Legal namestring
CellBri Bio Innovation Technology LTD
Websiteurl
cellbri.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

CellBri (CellBri Bio Innovation Technology LTD) is a Chinese-headquartered manufacturer of automated cell and gene therapy (CGT) manufacturing instruments, founded in 2020 and operating from Shenzhen with a global footprint spanning APAC, Europe, and North America. The company sells a dual-platform portfolio: the CellFAB One Series, an all-in-one enclosed system integrating sample preparation through final fill/formulation for clinical and commercial scale, and the Gentle Series, a suite of modular standalone units (Gentle Flex Pro for cell processing, Gentle n-MagS for nano-magnetic bead sorting, Gentle EXP for rocking-bioreactor expansion, Gentle P-Pac for fill and finish). Platforms are closed-system, 21 CFR Part 11 compliant, reagent-agnostic, and validated for Class C cleanroom operation; the company holds 260+ technical patents, ISO 13485 certification, FDA registration with DMFs on file, CE Marking, and EU MDR approval.

The company's commercial model is built on direct enterprise sales of capital equipment paired with recurring single-use consumables (cell bags, tubing sets, sterile samplers) and technical support services. It targets two primary customer segments: cell therapy developers and biotech companies running autologous and allogeneic programs (CAR-T, TCR-T, TIL, NK, MSC, iPSC), and CDMOs that need flexible automation to serve multiple client protocols. Distribution is supported by regional warehouses in Kansas City, MO and Budapest, Hungary enabling 3-5 business day shipping to North American and European customers. Named commercial deployment includes Grit Biotechnology's GT307 TIL program, which received FDA IND approval in February 2026 using CellBri's Gentle Flex-Pro and P-Pac systems.

CellBri monetizes via quote-based, multi-year enterprise contracts with undisclosed pricing. The company has scaled to 101-250 employees across 7 manufacturing centers with annual capacity of 5,000 instruments and 500,000 tubing sets, has secured 34+ GMP contract wins, and reports usage in 100+ pipeline products in China. It raised approximately $27.6M in mid-2024 led by 3E Bioventures and completed a subsequent financing in March 2025 with Changjin Holdings Industrial Capital and Fosun Health Capital. The company has no disclosed revenue figure, and ownership is private with no parent company or institutional investor profile publicly identified.

Short descriptiontext

CellBri is a Shenzhen-headquartered manufacturer of automated cell and gene therapy manufacturing instruments, selling modular and all-in-one closed-system platforms (CellFAB One, Gentle Series) plus single-use consumables to cell therapy developers, biotech companies, and CDMOs across APAC, Europe, and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy automation, automated cell processing, single-use consumables, bioreactor systems, fill and finish
Industry2 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cell Therapy Manufacturing Automation Equipment
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Automation Instruments and Platforms
TypeHardware Sales
Description

Sale of automated cell processing systems including CellFAB One Series and Gentle Series modular instruments. Systems are sold directly to biotech companies and CDMOs with enterprise sales motion.

cellbri.com
2Single-Use Consumables
TypeHardware Sales
Description

Single-use disposable kits, tubing sets, cell bags, samplers, and connectors. High-volume consumables business with 99% availability on critical components. Capacity to assemble half a million tubing sets per year.

cellbri.com
3Technical Support and Services
TypeProfessional Services
Description

Technical guidance and customer support services for implementation and ongoing operations.

cellbri.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise instrumentation and consumables sold via direct sales with quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly available; requires direct inquiry through sales team

cellbri.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1CellFAB One
Description

All-in-one automated cell processing system for clinical and commercial scale

cellbri.com
+7 more records
Core offering1 text field

CellBri designs, manufactures, and sells automated, closed-system cell therapy manufacturing instruments and single-use consumables for biotech companies and CDMOs. Its portfolio spans an all-in-one platform (CellFAB One Series) and modular units (Gentle Flex Pro, Gentle EXP, Gentle n-MagS, Gentle P-Pac) for processing CAR-T, TCR-T, TIL, NK, iPSC, and MSC therapies, complemented by consumables such as cell bags, tubing sets, samplers, and small tools (CB-Transfer, CB-LeakGuard). Revenue comes from direct sales of hardware and consumables together with technical support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 30% faster time to clinic
+5 more records
Product overview1 text field

CellBri offers a dual-platform portfolio of automated cell therapy manufacturing systems: the CellFAB One Series (all-in-one integrated platform) and the Gentle Series (modular standalone systems). The CellFAB One platform provides end-to-end automation from sample preparation to final fill, configurable for different magnetic selection methods (nanobeads/microbeads) and incubation formats. The Gentle Series offers step-specific automation through individual modules including Gentle Flex Pro (cell processing), Gentle n-MagS (magnetic separation), Gentle EXP (bioreactor expansion), and Gentle P-Pac (fill/finish). Both platforms support CAR-T, TCR-T, NK, TIL, iPSC, and MSC therapies with reagent-agnostic, closed-system design, 21 CFR Part 11 compliance, and compatibility with GMP Class C cleanroom environments. The portfolio also includes companion consumables (CB-Transfer, CB-LeakGuard, cell bags, tubing sets, samplers) for complete workflow support.

Product and service8 records
1CellFAB One
2Gentle Flex Pro
3Gentle EXP
4Gentle n-MagS
5Gentle P-Pac
6CB-Transfer
7CB-LeakGuard
8Small Tools & Consumables
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Bracco Imaging partnered with CellBri to codevelop a flexible closed cell selection system using Bracco's lipid-based microbubble technology as a bead-free alternative to traditional magnetic bead approaches for cell enrichment and activation. This collaboration supports automated cell therapy manufacturing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Bracco partnered with Limula along with University of Fribourg researchers to develop an automated cell selection alternative using lipid-based microbubble technology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Academic research partnership with University of Fribourg researchers collaborating with Bracco and Limula on automated cell selection technology development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

CellBri provides manufacturing technology support to Grit Biotechnology for their GT307 next-generation dual gene-knockout TIL therapy. CellBri's Gentle Flex-Pro (automated cell processing) and P-Pac (fill and finish) systems are used in the manufacturing workflow. GT307 received FDA IND approval in February 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

UK-based emerging player in automated cell and gene therapy manufacturing with the IRO platform. Competes directly with CellBri in closed-system cell therapy automation for both autologous and allogeneic workflows.

TypeDirect peer
Description

German-headquartered leader in cell processing instruments and reagents, including the Prodigy platform for automated cell therapy manufacturing. Closely comparable product offering (closed-system automation) and target customer base (biotech and CDMOs).

TypeBroad incumbent
Description

Global CDMO leader with the Cocoon automated cell therapy manufacturing platform. Overlaps with CellBri in cell therapy automation hardware but operates primarily as a CDMO services provider, offering automation as part of broader manufacturing services.

TypeBroad incumbent
Description

Danaher-owned life sciences tools provider with cell therapy automation solutions including the Sefia and Xuri cell expansion systems. Comparable in offering closed-system automation for cell therapy manufacturing to biotech and CDMO customers.

TypeDirect peer
Description

Specializes in blood component and cell processing equipment with cell therapy automation offerings. Direct competitor to CellBri in cell processing instruments for CAR-T and other cell therapy manufacturing workflows.

TypeBroad incumbent
Description

Global healthcare company with cell therapy manufacturing solutions including the Lovo and Feb CAT-S cell processing systems. Comparable automation offering targeting similar biotech and CDMO customers in cell therapy.

TypeEmerging player
Description

Joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf offering the G-Rex bioreactor platform for cell therapy manufacturing. Comparable focus on scalable cell expansion systems used in CGT workflows.

TypeBroad incumbent
Description

Provides cell sorting, washing, and processing instruments including the MoFlo Astrios and other cell therapy workflow tools. Comparable in providing instrumentation for cell therapy manufacturing, though broader portfolio.

TypeEmerging player
Description

US-based company offering single-use bioreactors for cell therapy and regenerative medicine manufacturing. Comparable in providing closed-system, GMP-compliant cell expansion platforms to cell therapy developers and CDMOs.

TypeEmerging player
Description

Emerging player in cell separation technology using microbubble-based approaches, directly comparable to CellBri's Bracco partnership strategy. Competes in cell isolation and activation workflows within cell therapy manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellbri

Cell Therapy Manufacturing Automation Equipmentcellbri.com

CellBri is a Shenzhen-headquartered manufacturer of automated cell and gene therapy manufacturing instruments, selling modular and all-in-one closed-system platforms (CellFAB One, Gentle Series) plus single-use consumables to cell therapy developers, biotech companies, and CDMOs across APAC, Europe, and North America.

What Cellbri does

CellBri (CellBri Bio Innovation Technology LTD) is a Chinese-headquartered manufacturer of automated cell and gene therapy (CGT) manufacturing instruments, founded in 2020 and operating from Shenzhen with a global footprint spanning APAC, Europe, and North America. The company sells a dual-platform portfolio: the CellFAB One Series, an all-in-one enclosed system integrating sample preparation through final fill/formulation for clinical and commercial scale, and the Gentle Series, a suite of modular standalone units (Gentle Flex Pro for cell processing, Gentle n-MagS for nano-magnetic bead sorting, Gentle EXP for rocking-bioreactor expansion, Gentle P-Pac for fill and finish). Platforms are closed-system, 21 CFR Part 11 compliant, reagent-agnostic, and validated for Class C cleanroom operation; the company holds 260+ technical patents, ISO 13485 certification, FDA registration with DMFs on file, CE Marking, and EU MDR approval.

The company's commercial model is built on direct enterprise sales of capital equipment paired with recurring single-use consumables (cell bags, tubing sets, sterile samplers) and technical support services. It targets two primary customer segments: cell therapy developers and biotech companies running autologous and allogeneic programs (CAR-T, TCR-T, TIL, NK, MSC, iPSC), and CDMOs that need flexible automation to serve multiple client protocols. Distribution is supported by regional warehouses in Kansas City, MO and Budapest, Hungary enabling 3-5 business day shipping to North American and European customers. Named commercial deployment includes Grit Biotechnology's GT307 TIL program, which received FDA IND approval in February 2026 using CellBri's Gentle Flex-Pro and P-Pac systems.

CellBri monetizes via quote-based, multi-year enterprise contracts with undisclosed pricing. The company has scaled to 101-250 employees across 7 manufacturing centers with annual capacity of 5,000 instruments and 500,000 tubing sets, has secured 34+ GMP contract wins, and reports usage in 100+ pipeline products in China. It raised approximately $27.6M in mid-2024 led by 3E Bioventures and completed a subsequent financing in March 2025 with Changjin Holdings Industrial Capital and Fosun Health Capital. The company has no disclosed revenue figure, and ownership is private with no parent company or institutional investor profile publicly identified.

Cellbri firmographics

Firmographics
Name
Cellbri
Legal name
CellBri Bio Innovation Technology LTD
Website
https://cellbri.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
CellBri is a Shenzhen-headquartered manufacturer of automated cell and gene therapy manufacturing instruments, selling modular and all-in-one closed-system platforms (CellFAB One, Gentle Series) plus single-use consumables to cell therapy developers, biotech companies, and CDMOs across APAC, Europe, and North America.
Ownership category
akta.pro rank

Cellbri industry classification

Industry
Product category
Cell Therapy Manufacturing Automation Equipment
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy automation
  • Automated cell processing
  • Single-use consumables
  • Bioreactor systems
  • Fill and finish

Where Cellbri is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Cellbri business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Automation Instruments and Platforms: Sale of automated cell processing systems including CellFAB One Series and Gentle Series modular instruments. Systems are sold directly to biotech companies and CDMOs with enterprise sales motion.
  2. Single-Use Consumables: Single-use disposable kits, tubing sets, cell bags, samplers, and connectors. High-volume consumables business with 99% availability on critical components. Capacity to assemble half a million tubing sets per year.
  3. Technical Support and Services: Technical guidance and customer support services for implementation and ongoing operations.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise instrumentation and consumables sold via direct sales with quote-based pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Cellbri product offering

Product offering

Core offering

CellBri designs, manufactures, and sells automated, closed-system cell therapy manufacturing instruments and single-use consumables for biotech companies and CDMOs. Its portfolio spans an all-in-one platform (CellFAB One Series) and modular units (Gentle Flex Pro, Gentle EXP, Gentle n-MagS, Gentle P-Pac) for processing CAR-T, TCR-T, TIL, NK, iPSC, and MSC therapies, complemented by consumables such as cell bags, tubing sets, samplers, and small tools (CB-Transfer, CB-LeakGuard). Revenue comes from direct sales of hardware and consumables together with technical support services.

Product overview

CellBri offers a dual-platform portfolio of automated cell therapy manufacturing systems: the CellFAB One Series (all-in-one integrated platform) and the Gentle Series (modular standalone systems). The CellFAB One platform provides end-to-end automation from sample preparation to final fill, configurable for different magnetic selection methods (nanobeads/microbeads) and incubation formats. The Gentle Series offers step-specific automation through individual modules including Gentle Flex Pro (cell processing), Gentle n-MagS (magnetic separation), Gentle EXP (bioreactor expansion), and Gentle P-Pac (fill/finish). Both platforms support CAR-T, TCR-T, NK, TIL, iPSC, and MSC therapies with reagent-agnostic, closed-system design, 21 CFR Part 11 compliance, and compatibility with GMP Class C cleanroom environments. The portfolio also includes companion consumables (CB-Transfer, CB-LeakGuard, cell bags, tubing sets, samplers) for complete workflow support.

Differentiator

Problem solved

Functional benefit

Brands

  • CellFAB One: All-in-one automated cell processing system for clinical and commercial scale
  • Gentle Series
  • Gentle Flex Pro
  • Gentle EXP
  • Gentle n-MagS
  • Gentle P-Pac
  • CB-Transfer
  • CB-LeakGuard

Products and services

  • CellFAB One
  • Gentle Flex Pro
  • Gentle EXP
  • Gentle n-MagS
  • Gentle P-Pac
  • CB-Transfer
  • CB-LeakGuard
  • Small Tools & Consumables

Quantifiable outcome

  • 30% faster time to clinic
  • +5 more outcomes

Companies that use Cellbri

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Cellbri technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Cellbri partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • BraccocoreStrategic or Co-development Partner · 4 February 2026Bracco Imaging partnered with CellBri to codevelop a flexible closed cell selection system using Bracco's lipid-based microbubble technology as a bead-free alternative to traditional magnetic bead approaches for cell enrichment and activation. This collaboration supports automated cell therapy manufacturing.
  • LimulaminorStrategic or Co-development Partner · 4 February 2026Bracco partnered with Limula along with University of Fribourg researchers to develop an automated cell selection alternative using lipid-based microbubble technology.
  • University of FribourgminorStrategic or Co-development Partner · 4 February 2026Academic research partnership with University of Fribourg researchers collaborating with Bracco and Limula on automated cell selection technology development.
  • Grit BiotechnologycoreStrategic or Co-development Partner · 1 February 2026CellBri provides manufacturing technology support to Grit Biotechnology for their GT307 next-generation dual gene-knockout TIL therapy. CellBri's Gentle Flex-Pro (automated cell processing) and P-Pac (fill and finish) systems are used in the manufacturing workflow. GT307 received FDA IND approval in February 2026.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Cellbri competitors and assessment

Company assessment

Emerging players

  • Ori Biotech: UK-based emerging player in automated cell and gene therapy manufacturing with the IRO platform. Competes directly with CellBri in closed-system cell therapy automation for both autologous and allogeneic workflows.
  • ScaleReady: Joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf offering the G-Rex bioreactor platform for cell therapy manufacturing. Comparable focus on scalable cell expansion systems used in CGT workflows.
  • PBS Biotech: US-based company offering single-use bioreactors for cell therapy and regenerative medicine manufacturing. Comparable in providing closed-system, GMP-compliant cell expansion platforms to cell therapy developers and CDMOs.
  • Akadeum Life Sciences: Emerging player in cell separation technology using microbubble-based approaches, directly comparable to CellBri's Bracco partnership strategy. Competes in cell isolation and activation workflows within cell therapy manufacturing.

Direct peers

  • Miltenyi Biotec: German-headquartered leader in cell processing instruments and reagents, including the Prodigy platform for automated cell therapy manufacturing. Closely comparable product offering (closed-system automation) and target customer base (biotech and CDMOs).
  • Terumo BCT: Specializes in blood component and cell processing equipment with cell therapy automation offerings. Direct competitor to CellBri in cell processing instruments for CAR-T and other cell therapy manufacturing workflows.

Broad incumbents

  • Lonza: Global CDMO leader with the Cocoon automated cell therapy manufacturing platform. Overlaps with CellBri in cell therapy automation hardware but operates primarily as a CDMO services provider, offering automation as part of broader manufacturing services.
  • Cytiva: Danaher-owned life sciences tools provider with cell therapy automation solutions including the Sefia and Xuri cell expansion systems. Comparable in offering closed-system automation for cell therapy manufacturing to biotech and CDMO customers.
  • Fresenius Kabi: Global healthcare company with cell therapy manufacturing solutions including the Lovo and Feb CAT-S cell processing systems. Comparable automation offering targeting similar biotech and CDMO customers in cell therapy.
  • Beckman Coulter Life Sciences: Provides cell sorting, washing, and processing instruments including the MoFlo Astrios and other cell therapy workflow tools. Comparable in providing instrumentation for cell therapy manufacturing, though broader portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellbri social profiles

Digital presence

Cellbri compliance and trust

Trust signal

Compliance4 records

Cellbri financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellbri leadership team

Management profile

Number of profiles

Cellbri funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellbri M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellbri

What does Cellbri do?

CellBri designs, manufactures, and sells automated, closed-system cell therapy manufacturing instruments and single-use consumables for biotech companies and CDMOs. Its portfolio spans an all-in-one platform (CellFAB One Series) and modular units (Gentle Flex Pro, Gentle EXP, Gentle n-MagS, Gentle P-Pac) for processing CAR-T, TCR-T, TIL, NK, iPSC, and MSC therapies, complemented by consumables such as cell bags, tubing sets, samplers, and small tools (CB-Transfer, CB-LeakGuard). Revenue comes from direct sales of hardware and consumables together with technical support services.

Is Cellbri a public or private company?

Cellbri is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellbri founded?

Cellbri was founded in 2020. It employs 11 to 50 people.

Where is Cellbri based?

Cellbri is headquartered in Los Angeles, United States, in the North America region.

How does Cellbri make money?

Three revenue lines are on record. Automation Instruments and Platforms are the primary driver. The others are single-Use Consumables and technical Support and Services.

Who are Cellbri's main competitors?

Emerging players on record are Ori Biotech, ScaleReady, PBS Biotech and Akadeum Life Sciences. Direct peers are Miltenyi Biotec and Terumo BCT. Broad incumbents are Lonza, Cytiva, Fresenius Kabi and Beckman Coulter Life Sciences.

Does Cellbri have an API?

No public API is recorded for Cellbri.

What industry is Cellbri in?

Cellbri's product category is Cell Therapy Manufacturing Automation Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageFrost & Sullivan presents the “Global CGT Industry Enabling Technology Innovation Leadership Award” to Shenzhen CellBri Bio-Innovation Technology Co., Ltd.Frost & Sullivan awarded Shenzhen CellBri Bio-Innovation Technology Co., Ltd. the Global CGT Industry Enabling Technology Innovation Leadership Award at its 2026 New Investment Event in Shanghai. CellBri's automated CGT platform, with over 400 patents, supports more than 200 organizations and 100+ advanced therapy pipelines, including CAR-T therapies.NewsfileFrost & Sullivan presents the "GLOBAL CGT INDUSTRY ENABLING TECHNOLOGY INNOVATION LEADERSHIP AWARD" to Shenzhen CellBri Bio-Innovation Technology Co., Ltd.Frost & Sullivan awarded Shenzhen CellBri Bio-Innovation Technology Co., Ltd. the Global CGT Industry Enabling Technology Innovation Leadership Award at the 2026 GIL Summit in Shanghai. CellBri's automated CGT manufacturing platform supports over 200 organizations and 100+ pipelines, with a 11,000-square-meter hub producing 500,000 consumable sets annually.FinancialContent Business PageFrost & Sullivan presents the "GLOBAL CGT INDUSTRY ENABLING TECHNOLOGY INNOVATION LEADERSHIP AWARD" to Shenzhen CellBri Bio-Innovation Technology Co., Ltd.Frost & Sullivan awarded Shenzhen CellBri Bio-Innovation Technology Co., Ltd. the Global CGT Industry Enabling Technology Innovation Leadership Award at its 2026 New Investment Event in Shanghai. CellBri's integrated automated CGT manufacturing platform supports over 200 organizations and 100+ pipelines, with a 11,000-square-meter hub delivering 500,000 consumable sets annually.